The positive interim results from the Phase 3 INSPIRE trial are a significant milestone for Applied Therapeutics, indicating potential for future revenue growth and increased investor confidence. Achieving primary and key secondary endpoints suggests the trial is on track for success, which can lead to regulatory approval and commercialization of the treatment. This news directly impacts the company's valuation and investor perception, likely leading to a short-term increase in stock price.